We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Infinity Initiates 2 Studies for Lead Candidate IPI-549
Read MoreHide Full Article
Infinity Pharmaceuticals Inc. has announced the initiation of two studies for its lead pipeline candidate-IPI-549, a first-in-class, oral immuno-oncology product candidate that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
Shares of the company have increased 2.6% compared with the industry’s growth of 6.5%.
The company initiated a phase II, MARIO-3 study in collaboration with Roche AG (RHHBY - Free Report) , evaluating IPI-549 in combination with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC), and in combination with Tecentriq. We note that, the combination of Tecentriq plus Abraxane is approved for TNBC. MARIO-3 is evaluating the addition of PI-549 to this regimen in both PDL1+ and PDL1- front-line TNBC patients. MARIO-3 also includes a cohort evaluating IPI-549 in combination with Tecentriq and Avastin (bevacizumab) in front-line PDL1+ and PDL1- renal cell cancer (RCC) patients.
Separately, Arcus Biosciences (RCUS - Free Report) has initiated a phase I/Ib study, in collaboration with Infinity, evaluating IPI-549 in a combination regimen with AB298, Arcus's dual adenosine receptor antagonist, and Doxil, a chemotherapy, in patients with advanced TNBC.
By partnering with leading pharmaceutical and biotech companies, Infinity is evaluating IPI-549 for various diseases. The company has a collaboration agreement with Bristol Myers (BMY - Free Report) to evaluate its lead pipeline candidate IPI-549 with the latter’s PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company expects to complete enrollment in the second half of 2019 in the expanded combination cohorts in MARIO-1, an ongoing phase I/Ib study of IPI-549 as a monotherapy, and in combination with Opdivo in approximately 220 patients with advanced solid tumors.
It’s Illegal in 42 States, But Investors Will Make Billions Legally
In addition to the companies you read about above, today you get details on the newly-legalized industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year. That’s twice as much as they spend on marijuana, legally or otherwise. Zacks special report revealing how investors can profit from this new opportunity. As more states legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special Report revealing 5 top stocks to watch in this space.
Image: Bigstock
Infinity Initiates 2 Studies for Lead Candidate IPI-549
Infinity Pharmaceuticals Inc. has announced the initiation of two studies for its lead pipeline candidate-IPI-549, a first-in-class, oral immuno-oncology product candidate that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
Shares of the company have increased 2.6% compared with the industry’s growth of 6.5%.
The company initiated a phase II, MARIO-3 study in collaboration with Roche AG (RHHBY - Free Report) , evaluating IPI-549 in combination with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC), and in combination with Tecentriq. We note that, the combination of Tecentriq plus Abraxane is approved for TNBC. MARIO-3 is evaluating the addition of PI-549 to this regimen in both PDL1+ and PDL1- front-line TNBC patients. MARIO-3 also includes a cohort evaluating IPI-549 in combination with Tecentriq and Avastin (bevacizumab) in front-line PDL1+ and PDL1- renal cell cancer (RCC) patients.
Separately, Arcus Biosciences (RCUS - Free Report) has initiated a phase I/Ib study, in collaboration with Infinity, evaluating IPI-549 in a combination regimen with AB298, Arcus's dual adenosine receptor antagonist, and Doxil, a chemotherapy, in patients with advanced TNBC.
By partnering with leading pharmaceutical and biotech companies, Infinity is evaluating IPI-549 for various diseases. The company has a collaboration agreement with Bristol Myers (BMY - Free Report) to evaluate its lead pipeline candidate IPI-549 with the latter’s PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company expects to complete enrollment in the second half of 2019 in the expanded combination cohorts in MARIO-1, an ongoing phase I/Ib study of IPI-549 as a monotherapy, and in combination with Opdivo in approximately 220 patients with advanced solid tumors.
Infinity currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Infinity Pharmaceuticals, Inc. Price
Infinity Pharmaceuticals, Inc. price | Infinity Pharmaceuticals, Inc. Quote
It’s Illegal in 42 States, But Investors Will Make Billions Legally
In addition to the companies you read about above, today you get details on the newly-legalized industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year. That’s twice as much as they spend on marijuana, legally or otherwise. Zacks special report revealing how investors can profit from this new opportunity. As more states legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special Report revealing 5 top stocks to watch in this space.
See these 5 “sin stocks” now>>